Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$46.27 +0.6%	$38.53	$21.72 ▼ $46.80	$8.73B	1.15	2.52 million shs	2.42 million shs
BHC Bausch Health Cos	$6.65 +0.8%	$5.42	$3.96 ▼ $9.85	$2.44B	0.41	2.61 million shs	2.27 million shs
GRFS Grifols	$9.75 +3.8%	$8.42	$6.19 ▼ $9.96	$6.46B	0.55	1.08 million shs	1.51 million shs
MRTX Mirati Therapeutics	$58.70	$58.82	$27.30 ▼ $64.41	$4.12B	0.77	2.76 million shs	N/A
RDY Dr. Reddy's Laboratories	$14.65 -0.8%	$14.79	$12.26 ▼ $16.89	$12.32B	0.33	1.52 million shs	2.05 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+0.63%	+5.87%	+15.42%	+36.45%	+74.27%
BHC Bausch Health Cos	+0.83%	-4.37%	+30.68%	+53.64%	-9.28%
GRFS Grifols	+3.83%	+7.44%	+8.09%	+44.23%	+9.43%
MRTX Mirati Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
RDY Dr. Reddy's Laboratories	-0.71%	-2.88%	-7.83%	+10.82%	-6.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.695 of 5 stars	4.5	2.0	0.0	3.9	2.3	3.3	0.6
BHC Bausch Health Cos	3.1031 of 5 stars	0.9	3.0	0.0	4.0	2.3	3.3	0.6
GRFS Grifols	3.6698 of 5 stars	1.5	5.0	0.0	0.0	2.6	0.0	5.0
MRTX Mirati Therapeutics	0.5526 of 5 stars	0.0	0.0	0.0	4.7	0.6	0.0	0.6
RDY Dr. Reddy's Laboratories	3.1991 of 5 stars	2.5	4.0	1.7	0.0	3.2	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	3.00	Buy	$58.93	27.36% Upside
BHC Bausch Health Cos	1.83	Reduce	$7.30	9.86% Upside
GRFS Grifols	3.00	Buy	$10.30	5.64% Upside
MRTX Mirati Therapeutics	0.00	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	3.00	Buy	$16.95	15.74% Upside

Current Analyst Ratings Breakdown

Latest BBIO, MRTX, BHC, GRFS, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$60.00
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/17/2025	GRFS Grifols	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.60 ➝ $10.30
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/5/2025	RDY Dr. Reddy's Laboratories	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/5/2025	RDY Dr. Reddy's Laboratories	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$14.44 ➝ $16.90
5/2/2025	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$8.50 ➝ $10.00
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	39.59	N/A	N/A	($7.71) per share	-6.00
BHC Bausch Health Cos	$9.63B	0.26	$7.82 per share	0.85	($0.89) per share	-7.47
GRFS Grifols	$7.81B	0.86	$0.97 per share	10.03	$13.55 per share	0.72
MRTX Mirati Therapeutics	$12.44M	331.01	N/A	N/A	$17.31 per share	3.39
RDY Dr. Reddy's Laboratories	$325.54B	0.04	$1.02 per share	14.29	$4.73 per share	3.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.43	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
GRFS Grifols	$169.80M	$1.17	8.33	9.29	0.34	N/A	N/A	N/A	7/29/2025 (Estimated)
MRTX Mirati Therapeutics	-$740.87M	-$12.22	N/A	N/A	N/A	-1,900.65%	-82.15%	-67.82%	N/A
RDY Dr. Reddy's Laboratories	$663M	$0.66	22.19	17.86	5.22	17.38%	17.98%	12.24%	7/25/2025 (Estimated)

Latest BBIO, MRTX, BHC, GRFS, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.50	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.9320	N/A	N/A	N/A	$2.47 billion	N/A
7/29/2025	Q2 2025	GRFS Grifols	$0.2221	N/A	N/A	N/A	$1.92 billion	N/A
7/25/2025	Q1 25/26	RDY Dr. Reddy's Laboratories	$0.19	N/A	N/A	N/A	$88.27 billion	N/A
5/9/2025	Q4 24/25	RDY Dr. Reddy's Laboratories	$0.20	$0.22	+$0.02	$0.22	$83.70 billion	$996.17 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.07	0.48%	N/A	10.61%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
BHC Bausch Health Cos	N/A	1.35	0.97
GRFS Grifols	1.13	2.60	0.97
MRTX Mirati Therapeutics	N/A	7.54	7.40
RDY Dr. Reddy's Laboratories	0.02	1.92	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BHC Bausch Health Cos	78.65%
GRFS Grifols	N/A
MRTX Mirati Therapeutics	N/A
RDY Dr. Reddy's Laboratories	3.85%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BHC Bausch Health Cos	8.05%
GRFS Grifols	0.19%
MRTX Mirati Therapeutics	3.26%
RDY Dr. Reddy's Laboratories	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
GRFS Grifols	23,822	687.55 million	686.25 million	Optionable
MRTX Mirati Therapeutics	587	70.15 million	67.86 million	Optionable
RDY Dr. Reddy's Laboratories	27,811	834.90 million	818.20 million	Optionable

BBIO, MRTX, BHC, GRFS, and RDY Headlines

Recent News About These Companies

Reviewing Supernus Pharmaceuticals (NASDAQ:SUPN) & Dr. Reddy's Laboratories (NYSE:RDY)

2 hours ago | americanbankingnews.com

Allspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)

July 9 at 3:32 AM | marketbeat.com

RDY - Dr Reddy's Laboratories Ltd ADR Valuation - Morningstar

July 2, 2025 | morningstar.comM

RDY Dr. Reddy's Laboratories Limited - Seeking Alpha

July 2, 2025 | seekingalpha.com

Bessemer Group Inc. Purchases 81,024 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)

June 27, 2025 | marketbeat.com

Dr. Reddy's Laboratories slips Thursday, underperforms competitors

June 26, 2025 | marketwatch.com

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Robeco Institutional Asset Management B.V.

June 26, 2025 | marketbeat.com

Dr. Reddy's Laboratories slips Monday, still outperforms market

June 23, 2025 | marketwatch.com

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Ritholtz Wealth Management

June 19, 2025 | marketbeat.com

GAMMA Investing LLC Purchases 66,049 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

June 17, 2025 | marketbeat.com

Rhumbline Advisers Sells 86,773 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

June 14, 2025 | marketbeat.com

Stanley Laman Group Ltd. Makes New $1.85 Million Investment in Dr. Reddy's Laboratories Limited (NYSE:RDY)

June 13, 2025 | marketbeat.com

Dr. Reddy's Laboratories rallies Tuesday, outperforms competitors

June 10, 2025 | marketwatch.com

Dr. Reddy's Laboratories Reaches Analyst Target Price

June 8, 2025 | nasdaq.com

HSBC Upgrades Dr. Reddy's Laboratories Limited - Depositary Receipt () (RDY)

June 6, 2025 | msn.com

HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold

June 5, 2025 | msn.com

Dr. Reddy's Laboratories rallies Thursday, outperforms competitors

June 5, 2025 | marketwatch.com

HSBC upgrades Dr Reddy’s on weight loss drug semaglutide-driven earnings rebound

June 5, 2025 | in.investing.com

Dr. Reddy’s stock rises on biosimilar collaboration with Alvotech

June 5, 2025 | investing.com

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

June 5, 2025 | zacks.com

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

June 5, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO, MRTX, BHC, GRFS, and RDY Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$46.27 +0.29 (+0.63%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$45.35 -0.92 (-2.00%)

As of 04:01 AM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Bausch Health Cos NYSE:BHC

$6.64 +0.06 (+0.83%)

Closing price 07/10/2025 03:59 PM Eastern

Extended Trading

$6.59 -0.06 (-0.89%)

As of 07/10/2025 06:35 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Grifols NASDAQ:GRFS

$9.75 +0.36 (+3.83%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$9.74 -0.02 (-0.15%)

As of 07/10/2025 07:30 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Dr. Reddy's Laboratories NYSE:RDY

$14.64 -0.12 (-0.78%)

Closing price 07/10/2025 03:59 PM Eastern

Extended Trading

$14.66 +0.02 (+0.11%)

As of 04:08 AM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time